Cargando…
Glycemic Control and Bone in Diabetes
PURPOSE OF REVIEW: This review summarizes recent developments on the effects of glycemic control and diabetes on bone health. We discuss the foundational cellular mechanisms through which diabetes and impaired glucose control impact bone biology, and how these processes contribute to bone fragility...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549036/ https://www.ncbi.nlm.nih.gov/pubmed/36214991 http://dx.doi.org/10.1007/s11914-022-00747-6 |
_version_ | 1784805575567081472 |
---|---|
author | Weber, David R. Long, Fanxin Zemel, Babette S. Kindler, Joseph M. |
author_facet | Weber, David R. Long, Fanxin Zemel, Babette S. Kindler, Joseph M. |
author_sort | Weber, David R. |
collection | PubMed |
description | PURPOSE OF REVIEW: This review summarizes recent developments on the effects of glycemic control and diabetes on bone health. We discuss the foundational cellular mechanisms through which diabetes and impaired glucose control impact bone biology, and how these processes contribute to bone fragility in diabetes. RECENT FINDINGS: Glucose is important for osteoblast differentiation and energy consumption of mature osteoblasts. The role of insulin is less clear, but insulin receptor deletion in mouse osteoblasts reduces bone formation. Epidemiologically, type 1 (T1D) and type 2 diabetes (T2D) associate with increased fracture risk, which is greater among people with T1D. Accumulation of cortical bone micro-pores, micro-vascular complications, and AGEs likely contribute to diabetes-related bone fragility. The effects of youth-onset T2D on peak bone mass attainment and subsequent skeletal fragility are of particular concern. SUMMARY: Further research is needed to understand the effects of hyperglycemia on skeletal health through the lifecycle, including the related factors of inflammation and microvascular damage. |
format | Online Article Text |
id | pubmed-9549036 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-95490362022-10-11 Glycemic Control and Bone in Diabetes Weber, David R. Long, Fanxin Zemel, Babette S. Kindler, Joseph M. Curr Osteoporos Rep Bone and Diabetes (A Schwartz and P Vestergaard, Section Editors) PURPOSE OF REVIEW: This review summarizes recent developments on the effects of glycemic control and diabetes on bone health. We discuss the foundational cellular mechanisms through which diabetes and impaired glucose control impact bone biology, and how these processes contribute to bone fragility in diabetes. RECENT FINDINGS: Glucose is important for osteoblast differentiation and energy consumption of mature osteoblasts. The role of insulin is less clear, but insulin receptor deletion in mouse osteoblasts reduces bone formation. Epidemiologically, type 1 (T1D) and type 2 diabetes (T2D) associate with increased fracture risk, which is greater among people with T1D. Accumulation of cortical bone micro-pores, micro-vascular complications, and AGEs likely contribute to diabetes-related bone fragility. The effects of youth-onset T2D on peak bone mass attainment and subsequent skeletal fragility are of particular concern. SUMMARY: Further research is needed to understand the effects of hyperglycemia on skeletal health through the lifecycle, including the related factors of inflammation and microvascular damage. Springer US 2022-10-10 2022 /pmc/articles/PMC9549036/ /pubmed/36214991 http://dx.doi.org/10.1007/s11914-022-00747-6 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Bone and Diabetes (A Schwartz and P Vestergaard, Section Editors) Weber, David R. Long, Fanxin Zemel, Babette S. Kindler, Joseph M. Glycemic Control and Bone in Diabetes |
title | Glycemic Control and Bone in Diabetes |
title_full | Glycemic Control and Bone in Diabetes |
title_fullStr | Glycemic Control and Bone in Diabetes |
title_full_unstemmed | Glycemic Control and Bone in Diabetes |
title_short | Glycemic Control and Bone in Diabetes |
title_sort | glycemic control and bone in diabetes |
topic | Bone and Diabetes (A Schwartz and P Vestergaard, Section Editors) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549036/ https://www.ncbi.nlm.nih.gov/pubmed/36214991 http://dx.doi.org/10.1007/s11914-022-00747-6 |
work_keys_str_mv | AT weberdavidr glycemiccontrolandboneindiabetes AT longfanxin glycemiccontrolandboneindiabetes AT zemelbabettes glycemiccontrolandboneindiabetes AT kindlerjosephm glycemiccontrolandboneindiabetes |